Psychedelic-Assisted Therapy in Palliative Care

Palliative care is a broad approach to care for people with serious illness that focuses on relieving suffering and optimizing quality of life at any stage of illness — including early stages when curative treatment is still being pursued. It addresses physical, psychological, social, and spiritual dimensions of suffering. End-of-life care is a subset of palliative care focused specifically on the period when a person is nearing death, typically the last weeks to months of life. Hospice care is a specialized program of end-of-life care that typically requires a prognosis of six months or less. Psilocybin research has primarily enrolled patients in palliative and end-of-life contexts, but the principles could extend earlier in the illness trajectory as research matures.

The primary symptom targets in palliative care psilocybin research are psychological and existential: depression, anxiety, demoralization (a loss of meaning and sense of purpose), existential distress (fear of death, confronting mortality), and hopelessness. Secondary outcomes studied include quality of life, spiritual well-being, relationship quality, and attitudes toward dying. Physical symptom management — pain, nausea, dyspnea — remains the domain of standard palliative pharmacotherapy, though some research has examined whether improvements in psychological distress secondarily reduce the subjective experience of physical symptoms. Psilocybin is not proposed as a pain medication but as a targeted intervention for the psychological and existential dimensions that standard care insufficiently addresses.

Sessions typically involve extensive preparation (2-4 meetings over several weeks) in which participants discuss their illness, psychological concerns, spiritual background, intentions for the session, and expectations. The psilocybin session itself lasts approximately 6-8 hours, with the participant lying on a comfortable couch, wearing an eye mask to encourage inner focus, listening to a curated music playlist, and accompanied by two trained guides throughout. Guides offer supportive presence, gentle guidance if the participant is distressed, and physical care (water, blankets). After the session, integration therapy involves 2-4 or more additional meetings to explore the meaning and content of the experience and connect it to the participant's ongoing life, illness, and relationships.

Integration therapy is widely considered by researchers and clinicians to be as important as the psilocybin session itself. The session creates an experience of unusual depth and significance, but the therapeutic work of understanding, contextualizing, and translating that experience into lasting change happens primarily in the days and weeks following. Integration therapists help participants articulate what they experienced, identify themes and insights, connect the experience to their personal history and current life circumstances, and make concrete shifts in perspective, relationship, or behavior that the experience may have made possible. In palliative care specifically, integration therapy often addresses topics such as reconciliation with family members, acceptance of the reality of dying, life review and legacy, and spiritual meaning-making.

Family involvement varies by protocol, but most palliative care psilocybin programs recognize that the dying process is inherently relational and attempt to include family members or significant others in some components. Preparatory sessions may include a family member to provide psychoeducation and create space for discussing the approaching death and the purpose of the therapy. Some programs invite a trusted companion to be present briefly during portions of the session. Integration therapy often includes sessions that explicitly focus on family relationships, communication, and the relational legacy the patient hopes to leave. Family members who participate in even limited ways consistently report that the process improved communication, intimacy, and the quality of remaining time together.

Hospice patients can participate in psilocybin research under clinical trial protocols if they meet eligibility criteria and the hospice facility permits trial participation. In Oregon and Colorado, psilocybin service centers operate under state law and may serve individuals who are not enrolled in clinical trials, potentially including those in hospice contexts, though the specific interaction between hospice program rules and psilocybin service access varies. Canada's Section 56 exemptions have been granted to some palliative and hospice patients. Access remains limited and requires navigating both regulatory frameworks and individual hospice program policies. Advocacy organizations and clinical trial networks are the most practical starting point for families or patients seeking information about access options.

Psilocybin is not FDA-approved for any indication as of 2026, meaning it cannot be routinely prescribed in the United States. It has received FDA Breakthrough Therapy designation for treatment-resistant depression, which expedites review but does not constitute approval. Access outside of clinical trials in the US is primarily through Oregon's Measure 109 service centers and Colorado's Proposition 122 framework. In Canada, Health Canada has granted Section 56 exemptions for therapeutic use to specific patients, including some with serious illnesses. In Australia, the Therapeutic Goods Administration approved psilocybin for treatment-resistant depression in 2023, creating a prescriber pathway through authorized prescribers. The regulatory landscape continues to evolve, and clinical trial access remains the most common route for palliative care patients.

Standard exclusion criteria include: personal or family history of psychosis, schizophrenia spectrum disorders, or bipolar I disorder (due to risk of precipitating psychotic episodes); active suicidal ideation with intent; current use of lithium (serious interaction risk) or tramadol; uncontrolled cardiovascular conditions or a recent cardiac event; pregnancy or breastfeeding; active substance use disorders (with some exceptions in addiction-specific trials); and significant cognitive impairment that would prevent adequate informed consent or safe participation. Medical exclusions vary by protocol. Some exclusions are relative rather than absolute — for example, controlled anxiety or prior psychedelic use — and are assessed on a case-by-case basis by the research team.

Spiritual dimensions are central to the research in this area, not peripheral. The mystical-type experiences that psilocybin reliably induces — characterized by a sense of unity, transcendence, sacredness, and deeply felt positive mood — have a quality that many participants describe in explicitly spiritual terms regardless of prior religious background. In palliative care, these experiences often involve encounters with a sense of larger meaning, connection to something beyond individual identity, or profound shifts in how the participant relates to their own approaching death. Research has found that measures of spiritual well-being improve significantly following psilocybin sessions in this population. Palliative care programs working with psilocybin increasingly incorporate chaplaincy and spiritual care perspectives into their protocols, recognizing that these dimensions deserve careful, respectful attention.

Long-term follow-up data from end-of-life and palliative psilocybin studies consistently show that benefits measured immediately after sessions are substantially maintained at 6-month follow-up — the longest timeframe most trials have assessed given the nature of the population. The Hopkins long-term follow-up, which assessed participants approximately 4.5 years after their psilocybin sessions, found that the majority still attributed lasting positive changes in their lives to the experience and rated it among the most meaningful events of their entire lives. While specific quality of life measures at this extended timeframe are difficult to assess in a terminal population, the subjective reports suggest that the experiential and psychological benefits are durable. Many participants also report that the session improved relational quality and communication in their remaining time, suggesting benefit that extended beyond the individual.